Public Citizen Xenical follow-up
This article was originally published in The Tan Sheet
Executive Summary
"Four researchers interviewed by the Cancer Letter objected to the fact that FDA advisory committee members who met on Jan. 23 to consider the over-the-counter switch of orlistat [GlaxoSmithKline's proposed OTC weight-loss drug, Alli] were not informed at or prior to the meeting about pre-cancerous changes...induced by orlistat in the colon of animals," Public Citizen states in a June 5 letter. The group submitted the letter as a supplement to its April 10 petition to ban the sale of Rx orlistat (Xenical), which also cited the link between the drug and the development of aberrant crypt foci (ACF) in rats (1"The Tan Sheet" April 17, 2006, p. 3). Although ACF may not have a causal link to polyps or colon cancer, it may be a surrogate marker for the disease. The group urges the inclusion of the animal ACF data in the agency's decision-making process on the drug and recommends that FDA remove the drug from the market...
You may also be interested in...
Xenical Off-The-Market Switch Sought By Public Citizen
Public Citizen is calling for prescription weight-loss drug Xenical (120 mg orlistat) to be pulled from the market days after FDA issued an "approvable" letter for an OTC version
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.